SGLT2 Inhibition by Dapagliflozin Protect against Diabetic Ketoacidosis by Suppressing Inflammation and Modulation of Ketone Production

Project: Other project

StatusActive
Effective start/end date6/1/1812/30/21

Funding

  • AstraZeneca LP: $123,869.00